During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed therapy and drugs could further improve the oncologic outcomes. Herein a narrative review is performed regarding the main rationale in combining immunotherapy and target therapies with SBRT looking at the available clinical data in case of oligometastatic NSCLC, Melanoma and Kidney cancer.
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Alongi, Filippo
2020-01-01
Abstract
During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed therapy and drugs could further improve the oncologic outcomes. Herein a narrative review is performed regarding the main rationale in combining immunotherapy and target therapies with SBRT looking at the available clinical data in case of oligometastatic NSCLC, Melanoma and Kidney cancer.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Mazzola_et_al-2020-Radiation_Oncology.pdf
accesso aperto
Tipologia:
Full Text
Licenza:
PUBBLICO - Pubblico senza Copyright
Dimensione
619.39 kB
Formato
Adobe PDF
|
619.39 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.